Quantitation of Minimal Residual Disease in Acute Myeloid Leukemia by Tryptase Monitoring Identifies a Group of Patients with a High Risk of Relapse
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Purpose: Recent data suggest that tryptase is produced by blast cells in a group of patients with acute myeloid leukemia (AML). In these patients, serum tryptase levels are elevated at diagnosis and decrease to normal (<15 ng/mL) or near normal values in those achieving complete hematologic remission (CR) after chemotherapy. Patients: In this study, we examined the value of tryptase as a marker of minimal residual AML. In 61 patients with de novo AML exhibiting elevated serum tryptase (>15 ng/mL) at diagnosis, tryptase levels were measured serially during and after chemotherapy by a fluoroenzyme immunoassay. Results: Of the 61 patients, 42 (68.9%) entered hematologic CR in response to induction chemotherapy. Twenty-nine of these 42 patients also entered biochemical remission (BR) defined by a decrease of tryptase levels to normal (<15 ng/mL). The remaining 13 patients exhibited elevated enzyme levels despite of hematologic CR. As assessed by multivariate analysis, the elevated tryptase in CR was found to be an independent prognostic variable concerning disease-free survival. Thus, AML relapses occurred in 15 of 29 patients with CR + BR (52%) and in 12 of 13 patients with CR without BR (92%), resulting in a significantly reduced probability of continuous CR for patients with CR without BR (P < 0.05). In all patients with continuous hematologic CR, tryptase levels remained constantly normal, whereas a recurrent elevation of tryptase in CR was invariably followed by a hematologic relapse. Conclusion: A persistently elevated tryptase level in AML in CR is indicative of minimal residual AML and associated with a high risk of relapse.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis
Schwartz, L. B., Metcalfe, D. D., Miller, J. S., Earl, H., & Sullivan, T. (1987) · New England Journal of Medicine · doi:10.1056/nejm198706253162603 · Cited by 784
Development of a new, more sensitive immunoassay for human tryptase: use in systemic anaphylaxis
Schwartz, L. B., Bradford, T. R., Rouse, C., Irani, A.-M., Rasp, G., Van Der Zwan, J. K., & Van Der Linden, P.-W. G. (1994) · Journal of Clinical Immunology · doi:10.1007/bf01533368 · Cited by 263
Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia
Sperr, W. R., Jordan, J.-H., Baghestanian, M., Kiener, H.-P., Samorapoompichit, P., Semper, H., Hauswirth, A., Schernthaner, G.-H., Chott, A., Natter, S., et al. (2001) · Blood · doi:10.1182/blood.v98.7.2200 · Cited by 149
Self-citation
Cited by
Hematopoietic Stem-Cell Transplantation for Advanced Systemic Mastocytosis
Ustun, C., Reiter, A., Scott, B. L., Nakamura, R., Damaj, G., Kreil, S., Shanley, R., Hogan, W. J., Perales, M.-A., Shore, T., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.2018 · Cited by 190
Self-citationSperr, W. R., El‐Samahi, A., Kundi, M., Girschikofsky, M., Winkler, S., Lutz, D., Endler, G., Rumpold, H., Agis, H., Sillaber, C., et al. (2009) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2009.02184.x · Cited by 98
Self-citationThe serum tryptase test: an emerging robust biomarker in clinical hematology
Valent, P., Sperr, W. R., Sotlar, K., Reiter, A., Akin, C., Gotlib, J., Horny, H.-P., & Arock, M. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.955008 · Cited by 83
“In addition, tryptase is recommended as a diagnostic and prognostic parameter in patients with known mastocytosis, CEL, CML and AML.”
InfluentialSelf-citationElevated Serum Tryptase in Non-Anaphylaxis Cases: A Concise Review
Lee, A. Y. S. (2020) · International Archives of Allergy and Immunology · doi:10.1159/000506199 · Cited by 36
Metadata
- Authors
- Sperr, W. R., Mitterbauer, M., Mitterbauer, G., Kundi, M., Jäger, U., Lechner, K., & Valent, P.
- Venue
- Clinical Cancer Research
- Published
- 2005-09-15
- Volume
- 11
- Issue
- 18
- Pages
- 6536-6543
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2142324226
- Cited by
- 19
- References
- 3
- FWCI
- 0.54
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Quantitation of Minimal Residual Disease in Acute Myeloid Leukemia by Tryptase Monitoring Identifies a Group of Patients with a High Risk of Relapse. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-05-0732
- The paper
- Sperr, W. R., Mitterbauer, M., Mitterbauer, G., Kundi, M., Jäger, U., Lechner, K., & Valent, P. (2005). Quantitation of Minimal Residual Disease in Acute Myeloid Leukemia by Tryptase Monitoring Identifies a Group of Patients with a High Risk of Relapse. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-05-0732
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.